Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics, Safety and Tolerability of GP681 Single Oral Dose in Male and Female Patients With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) as Compared With GP681 Administration to Male and Female Healthy Subjects

NCT05814926 is registered in ClinicalTrials.gov with Jiangxi Qingfeng Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT05814926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05814926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics, Safety and Tolerability of GP681 Single Oral Dose in Male and Female Patients With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) as Compared With GP681 Administration to Male and Female Healthy Subjects
Lead sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
April 26, 2023
Completion date
October 20, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, hepatic impairment